ARCHIVES

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Clinical Trials Working Group is looking for pragmatic solutions to improve cancer clinical trials system, Institute official says.

September 24, 2004

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

HIPAA Interpretations Vary, Delay Research, ASCO Study Finds

July 31, 2009

NCI Says Review Group Will Read Blueprint, Evaluate NCI Research

January 16, 1998

Six Surgical Oncology Grants To Be Funded

June 8, 1984

Centers Program Debate Turns Into Full Review Of All issues; Massive Survey, Hearings Planned

October 23, 1987